Mablink Bioscience products

Antibody–drug conjugates (ADCs) are a unique class of targeted immuno-oncology therapeutics that combine the tumor-targeting selectivity, stability, and favorable pharmacokinetic profile of monoclonal antibodies, with the potent antitumor activity of cytotoxic drugs. The ultimate goal of ADCs is to increase the therapeutic index of potent chemical agents, by the selective delivery of the chemotherapy to the tumor, whilst sparing the healthy tissues.

Most of the challenges of ADCs are linked to the hydrophobicity of the cytotoxic drugs used, which degrade the pharmacological properties of the antibody when attached to it.